Agenus reports no recurrences in Phase 2 NEST trial of botensilimab plus balstilimab in resectable colon cancer
AGEN•Updated Phase 2 NEST results show no observed recurrences
Agenus reported peer-reviewed updated Phase 2 NEST results for pre-surgery botensilimab with balstilimab in resectable colon cancer.
Earlier findings were presented at the 2025 ASCO Gastrointestinal Cancers Symposium; the new publication adds longer follow-up through March 31, 2026.
Updated data showed deep tumor shrinkage with no observed colorectal cancer recurrences during follow-up.
Most evaluable patients cleared circulating tumor DNA before surgery; treatment did not disrupt planned surgical timing.
Results underpin the planned global Phase 3 ROBBIN trial in high-risk Stage II or Stage III MSS colon cancer.
